76 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
ADUS Addus HomeCare Corporation $68.95 $806.53M N/A
Article Searches
Jazz Initiates Phase III Study for Narcolepsy Candidate http://www.zacks.com/stock/news/253080/jazz-initiates-phase-iii-study-for-narcolepsy-candidate?cid=CS-ZC-FT-253080 Mar 16, 2017 - Jazz Pharmaceuticals plc (JAZZ) recently announced the initiation of patient enrollment in a phase III study evaluating the efficacy and safety of its pipeline candidate, JZP-258, for the potential treatment of adult narcolepsy patients.
New Strong Buy Stocks for May 17th http://www.zacks.com/commentary/114108/new-strong-buy-stocks-for-may-17th?cid=CS-ZC-FT-114108 May 17, 2017 - New Strong Buy Stocks for May 17th
Addus Homecare's (ADUS) CEO, Dirk Allison on Q4 2015 Results - Earnings Call Transcript http://seekingalpha.com/article/3957205-addus-homecares-adus-ceo-dirk-allison-q4-2015-results-earnings-call-transcript?source=feed_all_articles Mar 10, 2016 - Addus Homecare Corporation (NASDAQ:ADUS) Q4 2015 Earnings Conference Call March 8, 2016 9:00 am ET Executives Dirk Allison - President, Chief Executive Officer Don Klink - Executive Vice President, Ch
Peek Into Aug 1 Healthcare Stocks' Q2 Earnings: ADUS, THC http://www.zacks.com/stock/news/225741/peek-into-aug-1-healthcare-stocks-q2-earnings-adus-thc?cid=CS-ZC-FT-225741 Jul 29, 2016 - Here, we take a sneak peek at two healthcare stocks scheduled to report their second-quarter figures on Aug 1.
Addus HomeCare's (ADUS) CEO Dirk Allison on Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3994632-addus-homecares-adus-ceo-dirk-allison-q2-2016-results-earnings-call-transcript?source=feed_sector_healthcare Aug 02, 2016 - Addus HomeCare Corporation (NASDAQ:ADUS) Q2 2016 Results Earnings Conference Call August 2, 2016 9:00 a.m. ET Executives Dirk Allison - President and Chief Executive Officer Brian Poff - Executive Vic
Keryx's Auryxia Added to Largest Medicare Part D Plan http://www.zacks.com/stock/news/253757/keryxs-auryxia-added-to-largest-medicare-part-d-plan?cid=CS-ZC-FT-253757 Mar 22, 2017 - Keryx Biopharmaceuticals, Inc. (KERX) announced that the nation's largest Medicare Part D plan sponsor has added Auryxia (ferric citrate) to its Medicare Part D plan formularies.
Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4 http://www.zacks.com/stock/news/253014/catalyst-cprx-reports-narrower-than-expected-loss-in-q4?cid=CS-ZC-FT-253014 Mar 16, 2017 - Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 5 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate and also narrower than the loss of 7 cents in the year-ago quarter.
TrovaGene (TROV) Reports Wider-than-Expected Loss in Q4 http://www.zacks.com/stock/news/253024/trovagene-trov-reports-wider-than-expected-loss-in-q4?cid=CS-ZC-FT-253024 Mar 16, 2017 - TrovaGene Inc. (TROV) reported loss of 31 cents per share in the fourth quarter of 2016, 2 cents wider than the Zacks Consensus Estimate.
Alexion (ALXN) Files for Soliris' Label Expansion in Japan http://www.zacks.com/stock/news/253867/alexion-alxn-files-for-soliris-label-expansion-in-japan?cid=CS-ZC-FT-253867 Mar 23, 2017 - Alexion Pharmaceuticals, Inc. (ALXN) announced that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) for the label expansion for Soliris to treat patients with refractory generalized myasthenia gravis (gMG).
Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA http://www.zacks.com/stock/news/254097/roches-rituxan-gets-breakthrough-therapy-designation-by-fda?cid=CS-ZC-FT-254097 Mar 24, 2017 - Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

Pages: 123456...8

Page 1>